News that Kymab Ltd is to be acquired by Sanofi has led some to lament the sale of yet another UK firm, once again raising concerns about the country's ability to build sustainable biotech businesses.
Cambridge-based monoclonal antibody expert Kymab is going to become part of the French giant after Sanofi agreed a $1.1bn upfront...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

